Subscribe

ASCO’s Value Framework Promoting Accountability and Transparency

VBCC - August 2015, Vol 6, No 7 - VBCC Perspectives
Joseph Morse

The American Society of Clinical Oncology (ASCO) value framework essentially calls for accountability and transparency, which are qualities that are beneficial to providing complete care for patients and to improving positive patient outcomes.

At Therigy, we see evidence of this trend in our consulting and technology sections. Helping healthcare stakeholders track adherence and outcomes in ways that can be easily measured and reported on will be a primary focus for us in the next 5 years.

The main opportunities and challenges arising from these ASCO recommendations are:

  • The ASCO value framework is centered on evidence-based, appropriate-­use criteria that oncology care providers can use to discuss viable treatment options for individual patients as part of an overall treatment plan. Many patients feel overwhelmed by the treatment options they face as well as by the cancer diagnosis itself. Informing and educating patients by giving them the facts (ie, measurable data) about their options enable them to become a partner in their treatment plan, which should improve patient adherence and outcomes
  • Oncology care providers using the ASCO value framework have a better idea of the total cost of care, and can better communicate the expected out-of-pocket expenses to the patient. Costs should be considered when setting up a treatment plan, but coordinating this complex information can be cumbersome for providers and for pharmacy staff. Therigy is developing systems to support integrated settings that track and manage the complete patient journey (from benefit investigation through therapy management) for patients who require specialty pharmacy medications. We appreciate that the ASCO proposed payment reform moves toward an integrated care model that lets patients benefit from early intervention and the enhanced management of treatment complications
  • Oncology care providers are accountable for providing high-quality, evidence-based care that helps patients avoid treatment complications requiring emergency department visits and hospital admissions that would lead to additional out-of-pocket costs for the patient
  • The main challenge with the ASCO framework involves the changes regarding the payment model and how revenue is actualized, which could prove challenging to providers as a whole. It will require training and understanding, and providers will need to take the initiative to ensure that they are aware of what is happening, and the impact that these changes will have on their businesses
  • Education is key to understanding and finding ways to implement new business practices to be better prepared for what lies ahead.

Related Items
The NCCN Evidence Blocks and Clinical Practice Guidelines: Identifying Truth
Robert W. Carlson, MD, Al B. Benson III, MD, FACP
VBCC - March 2016, Vol 7, No 2 published on March 21, 2016 in Online First, VBCC Perspectives
The NCCN New Tool to Assess Value Discourages Patients’ Hope
Robert Goldberg, PhD
VBCC - November 2015, Vol 6, No 10 published on November 12, 2015 in VBCC Perspectives
AstraZeneca Commentary on Oncology Value Tools
Diane Sullivan
VBCC - October 2015, Vol 6, No 9 published on October 17, 2015 in VBCC Perspectives
The Role of Oncologists in Defining the Value of Cancer Therapy
Michael Kolodziej, MD
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Value Framework a Powerful Tool for Shared Decision-Making
Neil B. Minkoff, MD
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
Emerging Tools for Assessing Value: Pros and Cons
Kirby J. Eng, RPh
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Net Health Benefit: A Palliative Care Regimen Scores Higher than Active Treatment
Pamela Pelizzari, MPH, Bruce Pyenson, FSA, MAAA
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
Addressing the Value of New Cancer Treatment Options Using the ASCO Model
Philip E. Johnson, MS, RPh, FASHP
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
The Missing Elements in Our Value-Based Care Discussions
Kevin Cast
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Value Framework Abandons the Hippocratic Oath
Robert Goldberg, PhD
VBCC - July 2015, Vol 6, No 6 published on July 21, 2015 in VBCC Perspectives
Last modified: August 19, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology